BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today that it intends to commence in the second half of 2007 clinical development of seliciclib, the company’s orally available cyclin dependent kinase (CDK) inhibitor, as a treatment for patients with nasopharyngeal cancer (NPC). Seliciclib is Cyclacel’s most advanced targeted drug candidate and is currently in Phase IIb development as a third line treatment for patients with advanced non-small cell lung cancer (NSCLC).
